Waverley Pharma Inc (WAVE) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.024x

Based on the latest financial reports, Waverley Pharma Inc (WAVE) has a cash flow conversion efficiency ratio of 0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-65.14K ≈ $-47.12K USD) by net assets (CA$-2.73 Million ≈ $-1.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Waverley Pharma Inc market capitalisation for the company's overall valuation and market capitalisation.

Waverley Pharma Inc - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Waverley Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View WAVE stock price and chart for real-time trading data and today's change.

Waverley Pharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Waverley Pharma Inc ranked by their cash flow conversion efficiency. Review WAVE free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Recon Technology Ltd NASDAQ:RCON	-0.015x
Anexo Group Plc LSE:ANX	-0.057x
Cobra Resources PLC LSE:COBR	-0.060x
CABASSE S.A. EO -50 F:LB0	N/A
Chelverton UK Dividend Trust PLC LSE:SDV	0.022x
Inotiv, Inc. NASDAQ:NOTVQ	-0.014x
GRIT Real Estate Income Group LSE:GR1T	0.058x
ONETECH SOLUTIONS HOLDINGS BERHAD KLSE:03041	-0.145x

Annual Cash Flow Conversion Efficiency for Waverley Pharma Inc (2015–2025)

The table below shows the annual cash flow conversion efficiency of Waverley Pharma Inc from 2015 to 2025. Also see how large is Waverley Pharma Inc's balance sheet for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$-2.57 Million ≈ $-1.86 Million	CA$-611.03K ≈ $-442.01K	0.238x	+17.72%
2024-12-31	CA$-2.03 Million ≈ $-1.47 Million	CA$-410.19K ≈ $-296.73K	0.202x	-77.52%
2023-12-31	CA$-1.14 Million ≈ $-822.30K	CA$-1.02 Million ≈ $-738.66K	0.898x	+513.44%
2022-12-31	CA$1.09 Million ≈ $789.27K	CA$-237.06K ≈ $-171.49K	-0.217x	+51.33%
2021-12-31	CA$1.79 Million ≈ $1.29 Million	CA$-798.78K ≈ $-577.82K	-0.446x	-152.15%
2020-12-31	CA$2.04 Million ≈ $1.48 Million	CA$-361.70K ≈ $-261.65K	-0.177x	+64.34%
2019-12-31	CA$2.85 Million ≈ $2.06 Million	CA$-1.41 Million ≈ $-1.02 Million	-0.497x	-35.82%
2018-12-31	CA$3.97 Million ≈ $2.87 Million	CA$-1.45 Million ≈ $-1.05 Million	-0.366x	-1600.85%
2017-12-31	CA$5.06 Million ≈ $3.66 Million	CA$-108.69K ≈ $-78.62K	-0.021x	-100.23%
2016-12-31	CA$-11.62K ≈ $-8.41K	CA$-108.69K ≈ $-78.62K	9.350x	-9.27%
2015-12-31	CA$-10.55K ≈ $-7.63K	CA$-108.69K ≈ $-78.62K	10.306x	--

About Waverley Pharma Inc

V:WAVE Canada Biotechnology

Market Cap

$390.63K

CA$540.00K CAD

Market Cap Rank

#31181 Global

#1652 in Canada

Share Price

CA$0.01

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.03

All Time High

CA$0.60